This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Metabolic Availability of Lysine From White Maize

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Paul Pencharz, The Hospital for Sick Children
ClinicalTrials.gov Identifier:
NCT02018575
First received: December 17, 2013
Last updated: November 11, 2016
Last verified: November 2016
  Purpose
Our objective is to determine the metabolic availability of Lysine in white maize using the indicator amino acid oxidation (IAAO) technique in adult men.

Condition Intervention Phase
Healthy Adults Dietary Supplement: Crystalline Lysine Amino Acid Mix Dietary Supplement: White corn meal porridge Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From White Maize Protein, in Young Adult Men

Resource links provided by NLM:


Further study details as provided by Dr. Paul Pencharz, The Hospital for Sick Children:

Primary Outcome Measures:
  • Metabolic Availability of Lysine [ Time Frame: Baseline ]
    3 breath samples will be taken to provide a baseline F13CO2 measurement (Level of Phenylalanine oxidation). Breath samples will be collected and analyzed for 13CO2 enrichment.


Secondary Outcome Measures:
  • Metabolic Availability of Lysine [ Time Frame: 15 mins after intake of the fourth hourly meal (before tracer infusion) ]
    3 breath samples will be taken to provide a baseline F13CO2 measurement (Level of Phenylalanine oxidation). Breath samples will be collected and analyzed for 13CO2 enrichment.


Other Outcome Measures:
  • Metabolic availability of Lysine [ Time Frame: 30 mins after intake of the fourth hourly meal (before tracer infusion) ]
    3 breath samples will be taken to provide a baseline F13CO2 measurement (Level of Phenylalanine oxidation). Breath samples will be collected and analyzed for 13CO2 enrichment.

  • Metabolic Availability of Lysine [ Time Frame: 45 mins after intake of the fourth hourly meal (before tracer infusion) ]
    3 breath samples will be taken to provide a baseline F13CO2 measurement (Level of Phenylalanine oxidation). Breath samples will be collected and analyzed for 13CO2 enrichment.

  • Metabolic Availability of Lysine [ Time Frame: Post Tracer Infusion (between 150 and 240 min of tracer infusion) ]
    4 breath samples will be taken to provide F13CO2 measurement (Level of Phenylalanine oxidation). Breath samples will be collected and analyzed for 13CO2 enrichment.


Enrollment: 7
Study Start Date: December 2013
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: levels of lysine intake.
Randomly selected levels of lysine intake which are lower than the lysine requirement (previously derived).
Dietary Supplement: Crystalline Lysine Amino Acid Mix
Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
Dietary Supplement: White corn meal porridge
A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.

Detailed Description:
Our objective is to determine the metabolic availability of Lysine in white maize. 7 young, healthy, male adults will receive graded levels (29, 37,46 and 54%) of lysine requirement of 35 mg/kg/d as a crystalline AA mixture and a porridge of white cornmeal protein respectively.
  Eligibility

Ages Eligible for Study:   20 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy Adult males (20-49 years old)

Exclusion Criteria:

  • A history of recent weight loss or illness
  • Use of any medication at the time of entry into the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02018575

Locations
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G-1X8
Sponsors and Collaborators
The Hospital for Sick Children
Investigators
Principal Investigator: Paul B Pencharz, MD, PhD The Hospital for Sick Children, Toronto, Canada
  More Information

Responsible Party: Dr. Paul Pencharz, Professor of Paediatrics and Nutritional Sciences (Emeritus) University of Toronto, Senior Scientist Research Institute, The Hospital for Sick Children, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT02018575     History of Changes
Other Study ID Numbers: 0019850580 amendment
Study First Received: December 17, 2013
Last Updated: November 11, 2016

Keywords provided by Dr. Paul Pencharz, The Hospital for Sick Children:
lysine
bioavailability
amino acids
corn

ClinicalTrials.gov processed this record on June 23, 2017